A single-inhaler triple therapy improved lung function in adults and adolescents with inadequately controlled asthma and was ...

With greater understanding of the complex pathomechanisms of myalgic encephalomyelitis/chronic fatigue syndrome, researchers ...

Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months with agenT-797 plus anti-PD-1Evidence of immune activation and ...

Mozilla relieves developers: any-llm provides a central API for many LLMs in the background. A multi-tenant gateway manages ...

Q3 2025 Earnings Call November 6, 2025 5:00 PM ESTCompany ParticipantsScott Smith - Head of Investor RelationsKeyvan Mohajer ...

Q3 2025 Earnings Call Transcript November 6, 2025 Pharming Group N.V. beats earnings expectations. Reported EPS is $0.1, expectations were $0.05. Operator: Good day, and thank you for standing by.

Continuing to explore strategic alternatives focusing on maximizing stockholder value Presented results from Phase 1 clinical trial of ATH-1105 in healthy volunteers demonstrating a favorable safety ...

Lexeo Therapeutics, Inc. surges after FDA trial alignment for LX2006 in Friedreich’s ataxia. Click for more on LXEO stock ...

编者按：在充满挑战且快速发展的神经科学领域，鲜有领导者能像Stacie ...